Skip to content

Clinical Efficacy Study of Qingre Huashi Touzhen Decoction in Treating Chikungunya Fever

Clinical Efficacy Study of Qingre Huashi Touzhen Decoction in Treating Chikungunya Fever

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2026000351
Enrollment
Unknown
Registered
2026-02-11
Start date
2025-10-28
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chikungunya Fever

Interventions

Control group:The control group was only treated with Western medicines such as acetaminophen
Qingre Huashi Touzhen Decoction group:Based on the control group, the heat-clearing and moistening formula for rash rash was combined. The ingredients included: Patchouli 10g, kudzu root 15g, Aconitum

Sponsors

Guangdong Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Meet the diagnostic criteria for CF in both traditional Chinese and Western medicine; 2) Onset less than 7 days; 3) Age range: 18 to 70 years old; 4) The clinical data are complete as a whole, with good compliance and cooperative follow-up.

Exclusion criteria

Exclusion criteria: 1) Patients with acute gastrointestinal bleeding, cerebral hemorrhage, malignant tumors, aortic dissection, pulmonary embolism, acute infection and other acute and critical conditions of organs; 2) Special patients with mental disorders, pregnant women, tumors, etc., who have conditions that affect the tongue and pulse. 3) The treatment involves the intervention of other traditional Chinese medicines and Chinese patent medicines. 4) Insufficient data and follow-up failure; 5) Those who are considered unsuitable for inclusion by the researchers.

Design outcomes

Primary

MeasureTime frame
The TCM syndrome scores and treatment effective rates on the 3rd and 7th days of treatment;

Secondary

MeasureTime frame
The regression rate of the main symptoms (fever, joint pain and rash) on the 3rd and 7th days of treatment;The time for the main symptoms (fever, joint pain and rash) to subside;Incidence of adverse events;The occurrence of joint pain was followed up for 3 months in the long term;

Countries

China

Contacts

Public ContactZhuang Jieqin

Guangdong Provincial Hospital of Traditional Chinese Medicine

1004548400@qq.com137 6065 3929

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Mar 14, 2026